What is

Epi-C (Epigenetic Compounds) is a new spin-off biotech company operating in the field of epigenetics.

One of our primary aims is to develop novel drugs with anti-cancer properties.

Epi-C performs small molecule screenings, as well as biological and molecular characterisation of drugs.

Epi-C patents pending:

Patent 1 - Immune-sensor for mobile detection of inquinants

Patent 2 - Use of integrated epigenome signature for acute leukemia patient’s stratification

Drug Discovery

Epi-C has extensive expertise in high-throughtput drug screening and hit characterisation.

Epi-C provides access to several proprietary compound libraries.

Epi-C has already characterised 3 small molecules, currently in pre-clinical trials.